Preclinical profile of befloxatone, a new reversible MAO-A inhibitor

Journal of Affective Disorders

Volumn 51, Issue 3, 1998, Pages 287-303

  Curet, O ^a   Damoiseau Ovens, G ^a   Sauvage, C ^a   Sontag, N ^a   Avenet, P ^a   Depoortere, H ^a   Caille, D ^a   Bergis, O ^a   Scatton, B ^a  

^a SANOFI   (France)

Author keywords

Antidepressant; Autoradiography; Autoreceptor; Brain; Dorsal raphe nucleus; Locus coeruieus; Microdialysis; Monoamine oxidase inhibitor; Monoamines; Substantia nigra

Indexed keywords

5 HYDROXYTRYPTOPHAN; BEFLOXATONE; BROFAROMINE; CIMOXATONE; CLORGYLINE; DOPAMINE; FLUOXETINE; HARMALINE; IMIPRAMINE; IPRONIAZID; LAZABEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NIALAMIDE; NORADRENALIN; OXAZOLIDINONE DERIVATIVE; PARGYLINE; PHENELZINE; PHENETHYLAMINE; RESERPINE; SELEGILINE; SEROTONIN; TOLOXATONE; TRANYLCYPROMINE; TRITIUM; TYRAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; FORCED SWIMMING TEST; HYPOTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNED HELPLESSNESS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; STEREOTYPY; TREMOR;

ANIMALS; AUTORADIOGRAPHY; AUTORECEPTORS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOCUS COERULEUS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; OXAZOLES; PROTEIN BINDING; RAPHE NUCLEI; RATS; RECEPTORS, DRUG; RECEPTORS, NEUROTRANSMITTER; TISSUE DISTRIBUTION;

EID: 0032445967     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00225-0     Document Type: Article

References (81)

1. Aghajanian, G.K., 1978. Feedback regulation of central monoaminergic-neurons. Evidence from single-cell recording studies. In: Youdim, M.B.H., Lovenberg, W., Sharman, D.F., Lagnado, J.R. (Eds.), Essays in Neurochemistry and Neuropharmacology. Wiley, New York, pp. 1-32.
2. Bieck, P.R., Antonin, K.H., 1994. Tyramine potentiation during treatment with MAOIs. In: Kennedy, S.H. (Ed.), Clinical Advances in Monoamine Oxidase Inhibitor Therapies. American Psychiatry Press, Washington, DC, pp. 83-110.
3. Blackwell, B., 1981. Adverse effects of antidepressant drugs. Part 1: Monoamine oxidase inhibitors and tricyclics. Drugs 21, 201-219.
4. Blier, P., de Montigny, C., 1985. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 16, 949-955.
5. Blier, P., de Montigny, C., Azzaro, A.J., 1986. Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: electrophysiological studies in the rat CNS. Naunyn-Schmiedeberg's Arch. Pharmacol. 334, 253-260.
6. Buffoni, F., 1983. Biochemical pharmacology of amine oxidases. Trends Pharmacol. Sci. 4, 313-315.
7. Butcher, S.P., Fairbrother, I.S., Kelly, J.S., Arbuthnott, G.W., 1990. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J. Neurochem. 55, 981-988.
8. Caille, D., Bergis, O.-E., Fankhauser, C., Gardes, A., Adam, R., Charrieras, T., Grosset, A., Rovei, V., Jarreau, F.-X., 1996. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J. Pharmacol. Exp. Ther. 277, 265-277.
9. Callingham, B.A., Barrand, M.A., 1987. Some properties of semicarbazide-sensitive amine oxidases. J. Neural Transm. Suppl. 23, 37-54.
10. Campbell, I.C., Gallager, D.W., Hamburg, M.A., Tallman, J.F., Murphy, D.L., 1985. Electrophysiological and receptor studies in rat brain: effects of clorgyline. Eur. J. Pharmacol. 111, 355-364.
11. Cedarbaum, J.M., Aghajanian, G.K., 1977. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur. J. Pharmacol. 44, 375-385.
12. Celada, P., Artigas, F., 1993. Monoamine oxidase inhibitors increase peferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 347, 583-590.
13. Colzi, A., D'Agostini, F., Cesura, A.M., Borroni, E., Da Prada, M., 1993. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo. J. Pharmacol. Exp. Ther. 265, 103-111.
14. 2-adrenergic autoreceptors. Brain Res. 499, 18-26.
15. Curet, O., Damoiseau, G., Labaune, J.P., Rovei, V., Jarreau, F.X., 1994. Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. J. Neural Transm. Suppl. 41, 349-355.
16. Curet, O., Damoiseau, G., Aubin, N., Sontag, N., Rovei, V., Jarreau, F.X., 1996. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J. Pharmacol. Exp. Ther. 277, 253-264.
17. Crane, G.E., 1959. lproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatry Res. Resp. 8, 142-152.
18. Da Prada, M., Zürcher, G., Wüthrich, I., Haefely, W.E., 1988. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J. Neural Transm. Suppl. 26, 31-56.
19. Da Prada, M., Kettler, R., Keller, H.H., Burkard, W.P., Muggli-Managlio, D., Haefely, W.E., 1989. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J. Pharmacol. Exp. Ther. 248, 400-414.
20. de Montigny, C., Blier, P., Chaput, Y., 1984. Electrophysiologically-identified serotonin receptors in the rat CNS. Effect of antidepressant treatment. Neuropharmacology 23, 1511-1520.
21. Dennis, T., L'Heureux, T., Carter, C., Scatton, B., 1987. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 241, 642-649.
22. Eisenhofer, G., Goldstein, D.S., Stull, R., Keiser, H.R., Sunderland, T., Murphy, D.L., Kopin, I.J., 1986. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylaianine in plasma, and their responses to inhibition of monoamine oxidase. Clin. Chem. 32, 2030-2033.
23. Elsworth, J.D., Glover, V., Reynolds, G.P., Sandler, M., Lees, A.J., Phuapradit, P., Shaw, K.M., Stern, G.M., Kumar, P., 1978. Deprenyl administration in man: a selective monoamine oxidase-B inhibitor without the 'cheese effect'. Psychopharmacology 57, 33-38.
24. Fankhauser, C., Charieras, T., Caille, D., Rovei, V., 1994. Interaction of MAO inhibitors and dietary tyramine: a new experimental model in the conscious rat. J. Pharmacol. Toxicol. Methods 32, 219-224.
25. Fowler, C.J., Strolin Benedetti, M., 1983. Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J. Neurochem. 40, 510-513.
26. 3H]hydroxytryptamine in slices of the human neocortex. J. Neurochem. 59, 1293-1301.
27. Garrett, M.C., Soares da Silva, P., 1990. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Neuropharmacology 29, 875-879.
28. Goldstein, D.S., Eisenhofer, G., Stull, R., Folio, C.J., Keiser, H.R., Kopin, I.J., 1988. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J. Clin. Invest. 81, 213-220.
29. Haefely, W., Hurlimann, A., Thoenen, H., 1963. The responses to tyramine of the normal and denervated nictitating membrane of the cat: analysis of the mechanisms and sites of action. Br. J. Pharmacol. 21, 27-38.
30. Hasan, F., McCrodden, J.M., Kennedy, N.P., Tipton, K.F., 1988. The involvement of intestinal monoamine in the transport and metabolism of tyramine. J. Neural Transm. Suppl. 26, 1-9.
31. Jacobs, B.L., 1976. An animal behavior model for studying central serotonergic synapses. Life Sci. 19, 777-786.
32. Johnston, J.P., 1968. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1286-1297.
33. Kan, J.P., Strolin Benedetti, M., 1981. Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD780515. J. Neurochem. 36, 1561-1571.
34. Kato, T., Dong, B., Ishii, K., Kinemuchi, H., 1986. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem. 46, 1277-1282.
35. Kline, N.S., 1958. Clinical experience with iproniazid. J. Clin. Exp. Psychopathol. 19, 72-78.
36. Knoll, J., Magyar, K., 1972. Some puzzling pharmacological effects of monoamines oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5, 393-408.
37. Konradi, C., Svoma, E., Jellinger, K., Riederer, P., Denney, R., Thibault, J., 1988. Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26, 791-802.
38. Konradi, C., Kornhuber, J., Froelich, L., Fritze, J., Heinsen, H., Beckmann, H., Schulz, E., Riederer, P., 1989. Demonstration of monoamine oxidase A and B in the human brainstem by a histochemical technique. Neuroscience 33, 383-400.
39. Koulu, M., Scheinin, M., Kaarttinen, A., Kallio, J., Pyykko, K., Vuorinen, J., Zimmer, R.H., 1989. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br. J. Clin. Pharmacol. 27, 243-255.
40. Langer, S.Z., 1981. Presynaptic regulation of the release of catecholamines. Pharmacol. Rev. 32, 337-362.
41. Levitt, P., Pintar, J.E., Breakefield, X.O., 1982. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc. Natl. Acad. Sci. 79, 6385-6389.
42. Li, P.P., Warsh, J.J., Godse, D.D., 1986. Further characterization of brain 3,4-dihydroxyphenylethyleneglycol (DHPG) formation. Dependence on noradrenergic activity and site of formation. Naunyn-Schmiedeberg's Arch. Pharmacol. 332, 26-33.
43. Lipper, S., Murphy, D.L., Slater, S., Buchsbaum, M.S., 1979. Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 62, 123-128.
44. Mann, J., Gershon, S., 1980. L-Deprenyl, a selective monoamine oxidase type-B inhibitorin endogenous depression. Life Sci. 26, 877-882.
45. Mann, J.J., Aarons, S.F., Wilner, P.J., Keilp, J.G., Sweeney, J.A., Pearlstein, T., Frances, A.J., Kocsis, J.H., Brown, R.P., 1989. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. Arch. Gen. Psychiatry 46, 45-50.
46. Martin, L., Bakish, D., Joffe, R., 1994. MAOI treatment of depression. In: Kennedy, S.H. (Ed.), Clinical Advances in Monoamine Oxidase Inhibitor Therapies. American Psychiatry Press, Washington, DC, pp. 147-180.
47. 1D autoreceptors in human cerebral cortex. J. Neurochem. 60, 1179-1182.
48. Mendis, N., Pare, C.M.B., Sandier, M., Glover, V., Stem, G.M., 1981. Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73, 87-90.
49. Mercuri, N.B., Bonci, A., Siniscalchi, A., Stefani, A., Calabresi, P., Bernardi, G., 1996. Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study. Br. J. Pharmacol. 117, 528-532.
50. Murphy, D.L., Aulakh, C.S., Garrick, N.A., Sunderland, T., 1987. Monoamine oxidase inhibitors as antidepressants: implications for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders. In: Meltzer, H.Y. (Ed.), Psychopharmacology. The Third Generation of Progress. Raven Press, New York, pp. 545-552.
51. Oreland, L., Engberg, G., 1986. Relation between brain monoamine oxidase (MAO) activity and the firing rate of locus coeruleus neurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 333, 235-239.
52. Ortmann, R., Waldmeier, P.C., Radeke, E., Feiner, A., Delini-Stula, A., 1980. The effects of 5-HT uptake and MAO-inhibitors on L-5-HTP-induced excitation in rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 311, 185-192.
53. Ortmann, R., Shaub, M., Feiner, A., Lauber, J., Christen, P., Waldmeier, P.C., 1984. Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84, 22-27.
54. Pickar, D., Cohen, R.M., Jimerson, D.C., Murphy, D.L., 1981. Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology 74, 4-7.
55. Porsolt, R.D., Anton, G., Blavet, N., Jalfre, M., 1978. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47, 379-391.
56. Provost, J.C., Funck-Brentano, C., Rovei, V., D'Estanque, J., Ego, D., Jaillon, P., 1992. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin. Pharmacol. Ther. 52, 384-393.
57. Roberts, C., Watson, J., Burton, M., Price, G.W., Jones, B.J., 1996. Functional characterization of the 5-HT terminal autoreceptor in the guinea-pig brain cortex. Br. J. Pharmacol. 117, 384-388.
58. Robinson, D.S., Johnson, G.A., Nies, A., Corcella, J., Cooper, T.B., Albright, D., Howard, D., 1983. Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J. Clin. Psychopharmacol. 3, 282-287.
59. Rosenzweig, P., Patat, A., Curet, O., Durrieu, G., Dubruc, C., Zieleniuk, I., 1998. Clinical pharmacology of befloxatone: a mini review 51, 305-312.
60. 3H-Ro 41-1049 and H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J. Neurosci. 12, 1977-1999.
61. Scatton, B., 1982. Brain 3,4-dihydroxyphenylethyleneglycol levels are dependent on central noradrenergic neuron activity. Life Sci. 31, 495-504.
62. 2-adrenoceptors in vivo in the rat brain. In: Kalsner, S., Westfall, T.C. (Eds.), Presynaptic Receptors and the Question of Autoregulation of Neurotransmifter Release. Annals of the New York Academy of Sciences, New York, Vol. 604, pp. 514-527.
63. Scheinin, M., Koulu, M., Karhuvaara, S., Zimmer, R.H., 1990. Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Life Sci. 47, 1491-1499.
64. 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci. 49, 75-84.
65. Strolin Benedetti, M., Boucher, T., Carlsson, A., Fowler, C.J., 1983. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem. Pharmacol. 32, 47-52.
66. Strolin Benedetti, M., Dostert, P., 1985. Stereochemical aspects of MAO interactions. Reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol. Sci. 6, 246-251.
67. Thorpe, L.W., Westlund, K.N., Kochersperger, L.M., Abell, C.W., Denney, R.M., 1987. Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. J. Histochem. Cytochem. 35, 23-32.
68. Volz, H.P., Gleiter, C.H., Waldmeier, P.C., Struck, M., Müller, H.J., 1996. Brofaromine - a review of its pharmacological properties and therapeutic use. J. Neural Transm. 103, 217-245.
69. Von Euler, U.S., Lishajko, F., 1960. Release of noradrenaline from adrenergic transmitter granules by tyramine. Experientia 16, 376-377.
70. Waldmeier, P.C., Delini-Stula, A., Maitre, L., 1976. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 292, 9-14.
71. Waldmeier, P.C., Feiner, A.E., Tipton, K.F., 1983. The Monoamind oxidase inhibiting properties of CGP 11305 A. Eur. J. Pharmacol. 94, 73-83.
72. Waldmeier, P.C., Baumann, P.A., 1983. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 324, 20-26.
73. Waldmeier, P.C., 1987. Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J. Neural Transm. Suppl. 23, 55-72.
74. Westlund, K.N., Denney, R.M., Kochersperger, L.M., Rose, R.M., Abell, C.W., 1985. Distinct monoamine oxidase A and B populations in primate brain. Science 230, 181-183.
75. Westlund, K.N., Denney, R.M., Rose, R.M., Abell, C.W., 1988. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456.
76. Wheatley, D., 1970. Comparative trial of a new mono-amine oxidase inhibitor in depression. Br. J. Psychiatry 117, 573-574.
77. Wiliner, P., 1984. The validity of animal models of depression. Psychopharmacology 83, 1-16.
78. Willoughby, J., Glover, V., Sandler, M., 1988. Histochemical localisation of monoamine oxidase A and B in rat brain. J. Neural Transm. 74, 29-42.
79. Youdim, M.B.H., Finberg, J.P.M., 1985. Monoamine oxidase inhibitor antidepressants. In: Grahame-Smith, D.G. (Ed.), Psychopharmacology 2. Part 1: Preclinical Psychopharmacology. Elsevier, Amsterdam, pp. 35-70.
80. Youdim, M.B.H., Finberg, J.P.M., Tipton, K.F., 1988. Monoamine oxidase. In: Trendelenburg, U., Weiner, N. (Eds.), Catecholamines I. Handbook of Experimental Pharmacology. Springer, Berlin, Vol. 90, pp. 119-192.
81. Zeller, E.A., Bardsky, J., 1952. In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl-hydrasine. Proc. Soc. Exp. Biol. 81, 459-461.